What’s Ahead for Eloxx Pharmaceuticals, Inc. (ELOX) After Reaching 52-Week High?

May 20, 2018 - By Michael Collier

The stock of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) hit a new 52-week high and has $16.58 target or 6.00 % above today’s $15.64 share price. The 5 months bullish chart indicates low risk for the $510.77M company. The 1-year high was reported on May, 20 by Barchart.com. If the $16.58 price target is reached, the company will be worth $30.65M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock decreased 3.40% or $0.55 during the last trading session, reaching $15.64. About 32,013 shares traded. Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) has 0.00% since May 20, 2017 and is . It has underperformed by 11.55% the S&P500.

More notable recent Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) news were published by: Globenewswire.com which released: “Eloxx Pharmaceuticals Reports First Quarter 2018 Financial and Operating Results and Provides Business Update” on May 10, 2018, also Benzinga.com with their article: “Benzinga’s Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings” published on May 02, 2018, Benzinga.com published: “50 Biggest Movers From Yesterday” on April 27, 2018. More interesting news about Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) were released by: Nasdaq.com and their article: “Eloxx Pharmaceuticals To Report First Quarter 2018 Financial Results On May 10, 2018 and Host Webcast and …” published on May 01, 2018 as well as Streetinsider.com‘s news article titled: “Eloxx Pharmaceuticals (ELOX) Says FDA Granted Orphan-Drug Designation for ELX-02 for Treatment of Cystinosis” with publication date: April 27, 2018.

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. The company has market cap of $510.77 million. The Company’s lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.